Comparative Immunological Responses to GnRHa Monotherapy versus Dual Trigger

Overview

This pilot study investigates the immune responses associated with GnRH agonist (GnRHa) monotherapy versus dual trigger (GnRHa plus hCG) in women undergoing oocyte cryopreservation. Results are exploratory due to the small sample size.

Background

The choice of trigger for final oocyte maturation in assisted reproductive technology (ART) can influence clinical outcomes and immune responses. Understanding these differences is crucial, as immune modulation plays a significant role in follicular development and implantation. This study explores how different triggering methods affect immune profiles.

Data Highlights

No numerical data available due to the exploratory nature of the study.

Key Findings

• Dual trigger was associated with a lower CD4/CD8 T cell ratio compared to GnRHa alone.
• There was an increase in highly differentiated cytotoxic (CD57+) cell populations with dual trigger.
• Findings are exploratory due to the small sample size (n=5).
• No cases of ovarian hyperstimulation syndrome (OHSS) were reported in the study.

Clinical Implications

Clinicians should consider immunological differences when selecting oocyte maturation triggers in ART.

Conclusion

This pilot study provides insights into the immune responses associated with different oocyte maturation triggers.

Related Resources & Content

1. Frontiers in Endocrinology, 2026 -- The ovulation trigger method affects gonadotropin concentrations and gonadotropin receptor expression during final oocyte maturation in women
2. Frontiers in Endocrinology, 2026 -- Predictors of early response to GnRH and gonadotropin therapy in pediatric patients with suspected dual congenital hypogonadotropic hypogonadism: a retrospective single-center study
3. The Journal of Clinical Endocrinology & Metabolism, 2023 -- Oral Elagolix Offers a More Cost-Effective and Less Invasive Alternative to Injectable GnRH Antagonists for Ovulation Suppression in IVF
4. Frontiers in Endocrinology, 2026 -- Impact of GnRH Antagonist Protocols versus Progestin-Primed Ovarian Stimulation on Reproductive Outcomes in Advanced Reproductive Age Women: A Propensity Score-Matched Retrospective Cohort Study
5. American Society for Reproductive Medicine, 2023 -- Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline
6. ScienceDirect, 2026 -- Dual trigger vs. gonadotropin-releasing hormone agonist trigger for elective fertility preservation: a randomized controlled trial
7. ESHRE guideline update on ovarian stimulation
8. Prevention of moderate and severe ovarian hyperstimulation syndrome: a guideline (2023) - practice guidance | American Society for Reproductive Medicine | ASRM
9. Dual trigger vs. gonadotropin-releasing hormone agonist trigger for elective fertility preservation: a randomized controlled trial - ScienceDirect
10. Oocyte maturation triggering in high responders in IVF treatment: a systematic review and network meta-analysis